{"schema_version":"secwatch.filing_event.v1","accession":"0001770787-24-000064","form_type":"8-K","ticker":"TXG","cik":"0001770787","company_name":"10x Genomics, Inc.","filed_at":"2024-10-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.551235+00:00","generated_at":"2026-05-30T17:26:19.520086+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"10x Genomics preliminary Q3 revenue $151.7M, down 1% YoY; instruments revenue falls 46%","bullets":["Revenue of ~$151.7M, down 1% YoY; instruments revenue $19.1M (-46%), consumables $126.2M (+10%), services $6.4M (+48%).","Americas revenue $87.8M (-11% YoY); EMEA $37.9M (+18%); APAC $26.0M (+15%).","CEO cites commercial reorganization disruption and cautious customer spending on capital equipment as key headwinds.","Cash and equivalents ~$398M as of Sept 30; full-year 2024 guidance to be discussed on October 29 earnings call."],"urls":{"canonical":"https://secwatch.observer/filing/0001770787-24-000064","json":"https://secwatch.observer/filing/0001770787-24-000064.json","markdown":"https://secwatch.observer/filing/0001770787-24-000064.md","text":"https://secwatch.observer/filing/0001770787-24-000064.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1770787/000177078724000064/0001770787-24-000064-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1770787/000177078724000064/txg-20241009.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T17:26:19.520086+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}